<DOC>
	<DOCNO>NCT01323920</DOCNO>
	<brief_summary>A common problem stem cell transplant graft-versus-host-disease ( GVHD ) . GVHD complication transplantation donor graft attack damage tissue . After stem cell transplant , patient receive prophylactic medication GVHD . In research study , study safety effectiveness bortezomib base GVHD prophylaxic drug combination participant myeloablative allogeneic stem call transplantation match unrelated donor , mismatch relate unrelated donor .</brief_summary>
	<brief_title>Bortezomib-based GVHD Prophylaxis After Allogeneic Transplant Patients Without Matched Related Donors</brief_title>
	<detailed_description>Before transplant receive conditioning therapy fludarabine busulfan give 7 , 6 , 5 , 4 day transplant . On day 0 , receive select blood cell take sibling unrelated donor . You receive 3 drug GVHD prophylaxis : Tacrolimus start 3 day transplant . It give intravenously later mouth . You continue take tacrolimus 3 6 month transplant . Methotrexate give intravenously 1 , 3 , 6 11 day transplant . Bortezomib give intravenously 1 , 4 , 7 day transplant . On day 1 , 4 , 7 , 30 3 , 6 12 month transplant physical exam , blood work , ask complete questionnaire .</detailed_description>
	<mesh_term>Myelodysplastic Syndromes</mesh_term>
	<mesh_term>Preleukemia</mesh_term>
	<mesh_term>Methotrexate</mesh_term>
	<mesh_term>Tacrolimus</mesh_term>
	<mesh_term>Bortezomib</mesh_term>
	<criteria>Histologically cytologically confirm advanced and/or aggressive hematologic malignancy ( include myelodysplastic syndrome ) unlikely cure alternative therapy HLAMatched unrelated donor ; 1locus HLAmismatched relate unrelated donor ECOG performance status 02 Adequate organ function Able understand willing sign write informed consent document Agrees practice adequate contraception per study requirement Pregnant breastfeed Recipient prior allogeneic autologous stem cell transplantation Prior abdominal radiation therapy HIVpositive combination antiretroviral therapy Seropositive hepatitis B C Allergies bortezomib , boron , mannitol Myocardial infarction within last 6 month , NYHA Class III IV heart failure , uncontrolled angina , severe uncontrolled ventricular arrhythmia Uncontrolled bacterial , viral fungal infection Seizures history seizure History another nonhematologic malignancy unless diseasefree least 5 year Uncontrolled intercurrent illness</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>60 Years</maximum_age>
	<verification_date>December 2016</verification_date>
	<keyword>Stem Cell Transplant</keyword>
	<keyword>Allogeneic Transplant</keyword>
	<keyword>Donors</keyword>
</DOC>